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Abstract
Background: Transplantation improves survival and the quality of life of patients with end-stage organ failure.
Infection, due to surgical issues, host factors such as diabetes, immunosuppression, and hypogammaglobulinemia,
is a major post-transplant complication. Clinical outcomes of prophylaxis or treatment of hypogammaglobulinemia
in solid organ transplant recipients are not well established and are in need of further study.
Methods/design: We will conduct a systematic review of studies investigating clinically relevant outcomes of
immunoglobulin use either as prophylaxis or treatment of hypogammaglobulinemia after solid organ transplantation.
Both randomized and non-randomized studies (excluding case reports and case series of less than 20 subjects) will be
included. Outcomes of interest will include the overall rate of infection, hospital admission, hospital length of stay,
intensive care unit admission, 1-year all-cause mortality, incidence of acute organ rejection, allograft survival within
1 year, and adverse events. We will search MEDLINE, Embase, the Cochrane Central Register of Controlled Trials,
Transplant library, and the International Clinical Trials Registry Platform for randomized and non-randomized studies on
adult solid organ transplant patients who received prophylactic immunoglobulin or immunoglobulin treatment. Two
reviewers will conduct all screening and data collection independently. We will assess study level of risk of bias using
the Cochrane Risk of Bias Assessment Tool for randomized controlled trials and for non-randomized studies. If
meta-analysis of outcome data is deemed appropriate, we will use random effects models to combine data for
continuous and dichotomous measures.
Discussion: The results of this systematic review may inform guideline development for measuring immunoglobulin
level and use of immunoglobulin in solid organ transplant patients and highlight areas for further research.
Systematic review registration: PROSPERO CRD42015017620
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(IgG) <700 mg/dL or 7 g/L) is a complication of solid
organ transplantation (SOT) that occurs after immuno-
suppressive therapy or treatment of organ rejection [1].
The reported incidence of hypogammaglobulinemia
among kidney transplant recipients is between 40 and
60 % [2–5]. This is similar to the overall rate of hypo-
gammaglobulinemia in all SOT recipients [4]. The rate,
duration, and severity of hypogammaglobulinemia are
further modified by a variety of additional factors includ-
ing host and donor characteristics, presence of graft rejec-
tion, and its accompanying use of immunosuppressive
therapy [6–8].
Immunosuppression is vital in transplantation; how-
ever, it also increases risk of infection. Hypogam-
maglobulinemia is associated with an increased rate of
bacterial infection as compared to transplant recipients
without hypogammaglobulinemia (15 vs 5 %) [9]. Post-
transplant hypogammaglobulinemia is an independent
risk factor for overall (hazard ratio (HR) 2.03; 95 % con-
fidence interval (CI) 1.39–2.96) and bacterial infection
(HR 2.68; 95 % CI 1.66–4.34) in kidney transplant recipi-
ents [3]. Hypogammaglobulinemia is also an independ-
ent risk factor for Clostridium difficile-associated colitis
in heart transplantation recipients [10]. Severe hypogam-
maglobulinemia (IgG <4 g/L) is also a risk factor for
death following SOT [4]. It is not known whether the
increased risk of mortality is solely related to severe
infection as a result of hypogammaglobulinemia in this
population.
Intravenous immunoglobulin (IVIG) is prepared from
pooled plasma involving thousands of healthy blood do-
nors. The large donor pool ensures a diversity of anti-
body specificities to a wide spectrum of antigens and
microbial pathogens [11]. The use of IVIG or any form
of immunoglobulin in hypogammaglobulinemia after
solid organ transplantation has not been well explored.
A retrospective study looking at IVIG therapy and sur-
vival post-transplantation has been recently published
[12]. This study showed that increasing immunoglobulin
levels with IVIG did not have any impact on survival.
However, the study was limited by its retrospective
design and small sample size.
IVIG has been used in highly sensitized kidney trans-
plant recipients to permit successful transplantation and
reduce the risk of antibody-mediated rejection [13].
IVIG is thought to be effective in this setting by blocking
complement activation, neutralizing donor-specific anti-
bodies via anti-idiotypic HLA antibodies, and down-
regulating HLA antibody production by donor-specific
B-cells.
To date, clinical outcomes related to the prophylactic
or therapeutic use of immunoglobulin in SOT recipients
have not been analyzed. The planned systematic review
will address this knowledge gap in order to establish the
current state of the evidence on this topic.
Research objectives
We will conduct a systematic review to evaluate clinical
outcomes associated with the use of immunoglobulin
after solid organ transplantation.
Methods
Search strategy
A comprehensive electronic search will be conducted in
MEDLINE (1950 to September 2015), Embase (1950 to
September 2015), and the Cochrane Central Register of
Controlled Trials (September 2015). The assistance of a
medical librarian experienced in systematic reviews will be
used in designing the search strategy. A structured search
strategy will be based on controlled vocabulary and rele-
vant key terms and will be broad to prioritize sensitivity
(Additional file 1). Language of publication will not be re-
stricted, and the draft search will be peer reviewed by a
second medical librarian according to PRESS criteria [14].
The references of included articles and existing reviews
will be scanned for additional studies that were not
identified by the search. Transplant library search
(www.transplantevidence.com) will be performed in order
to identify studies that were published as conference
proceedings or only in abstract forms. We will search the
International Clinical Trials Registry Platform (www.who.
int/ictrp/en/) to identify incomplete or unreported studies.
Study screening and inclusion
Using the results of our comprehensive search strategy,
we will obtain title and abstract from all references. First
titles and abstracts (stage 1) and then full-texts of poten-
tially relevant studies (stage 2) will be screened by two
reviewers independently following short pilot exercises
to identify and address any inconsistencies in the appli-
cation of screening criteria. The inclusion and exclusion
criteria used for each stage of screening are outlined
below. If no abstract is available for a given citation, the
full-text will be obtained unless the article can be confi-
dently excluded by its title alone. In general, if there is
any doubt as to whether a study should be excluded, the
study will proceed to the full-text screen to reduce the
likelihood of excluding a relevant study. A third party
will reconcile any disagreements if discussion between
the two reviewers cannot determine the article’s inclu-
sion status. The process of study selection will be sum-
marized using a PRISMA flow diagram [15].
Study eligibility criteria
Studies will be selected according to the criteria outlined
in Table 1.
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Data extraction
Each eligible study will undergo a standardized data ex-
traction process by two reviewers independently using a
pre-designed form designed in Microsoft Excel (Microsoft
Corporation, Seattle, WA, USA). Any discrepancies will be
documented, discussed, and adjudicated by a third party.
Prior to extraction of all study data, piloting of the form
will first be conducted upon a small number of studies.
Information pertaining to study identification (author,
year of publication, number and location of centers, fund-
ing, and journal); study design (type of study, sample size,
eligibility criteria, and length of follow-up); aggregate
patient characteristics (age, gender, duration of end organ
damage prior to transplantation, type of transplantation,
immunosuppressive regimen, comorbidities, onset of
hypogammaglobulinemia, duration of hypogammaglobuli-
nemia, treatment with immunoglobulin therapy either
intravenously or subcutaneously, dose of immunoglobulin,
and duration of treatment); and infection outcomes (the
overall rate of infection as well as the rates of non-severe,
severe, and serious/fatal infections) will be extracted.
Hypogammaglobulinemia is defined as IgG level of less
than 7 g/L. Severe hypogammaglobulinemia is defined as
IgG level <4 g/L [4]. A serious/fatal infection will be
considered to be any infection that required admission to
intensive care unit or result in death. A severe infection
will be considered any infection that required intravenous
antimicrobial therapy and/or hospitalization. A non-
severe infection will be considered any infection that
does not meet criteria for severe or serious/fatal in-
fection [16, 17]. If available, etiologic agent of infection
will also be recorded as gram-positive, gram-negative, or
anaerobic bacteria; Candida spp.; filamentous fungi; or
viruses. Site of infection will be recorded as central ner-
vous system, respiratory tract, gastrointestinal, genitouri-
nary, skin, soft tissue, or blood stream infection related/
non-related to catheter. Infection at other sites not
specified above will be recorded as others. We will use
individual study’s definitions of infectious outcomes if they
do not align with the set definition above.
Risk of bias assessment
Risk of bias in the randomized trials will be evaluated
using the Cochrane Risk of Bias Assessment Tool [18].
Studies will be assessed based on the domains of
randomization, generation of allocation sequence, alloca-
tion concealment, blinding, follow-up, and reporting.
Non-randomized studies will be evaluated using the
ACROBAT-NRSI [19] based on study design, confound-
ing, reporting, and directness of evidence. Results from
risk of bias assessments will be presented in their en-
tirety. They will also be summarized narratively and may
also inform sensitivity analyses. If there are sufficient
numbers of trials (e.g., ≥ten studies), we will construct a
funnel plot to assess for possible publication bias.
Data analysis
For studies assessing the effect of immunoglobulin
treatment, we will report the overall rates of infection, non-
severe infection, severe infection, and serious/fatal infection
per 100 patient-days in patients receiving immunoglobulin
treatment for secondary hypogammaglobulinemia. We will
also report stratified infection rates for patients with severe
and non-severe hypogammaglobulinemia. Type of infection
(e.g., bacterial, viral) and site of infection will also be re-
ported. For studies assessing the effect of prophylactic im-
munoglobulin, we will report overall rates of infection and
mortality, as well as adverse events.
We will compare overall rates of infection in the inter-
vention and control (no IVIG) groups of each study and
report the corresponding relative risk measures along with
the corresponding with 95 % confidence interval. A rela-
tive risk of less than 1 will suggest a beneficial effect of
intravenous immunoglobulin, while a relative risk of
greater than 1 will suggest a harmful effect. Prior to con-
duct of meta-analyses, team members will review charac-
teristics of the included studies and their patient
populations such as type of study, outcome measures, and
organ transplanted to establish the extent to which they
appear homogeneous. The Cochrane Q/chi-square test
and I2 statistic will also be calculated to evaluate hetero-
geneity. We will use I2 cutoff of ≥75 % to be considered as
considerable heterogeneity [20]. Where meta-analysis is
Table 1 PICOS breakdown of study eligibility criteria
Category Description of criteria
Population Adults undergoing solid organ transplant (including the
heart, lung, liver, kidney, intestine, and pancreas)
Intervention Polyvalent immunoglobulin prophylaxis or polyvalent
immunoglobulin treatment without restriction to
dosage, frequency, timing, and route of administration
Comparator(s) Placebo or no treatment. Patients may receive
antimicrobial prophylaxis, which should be the same in
both intervention and control arms
Outcome(s) Primary outcome:
1) Overall rate of infection
2) Rate of infection based on severity: non-severe
infection, severe infection, and serious/fatal infection
Secondary outcomes:
1) Hospital admission, initial length of stay, and number
of re-admissions in the first year after transplantation;
2) ICU admission;
3) 1-year all-cause mortality;
4) Incidence of acute rejection;
5) Allograft survival at 1 year after transplantation
6) Adverse events graded by severity [21]
Study design Both randomized controlled trials and non-randomized
studies including case series with a minimum of 20
cases will be included. Case reports and studies that
only focus on immunoglobulin use for de-sensitization
purposes will be excluded
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considered to be appropriate, we will pool data using a
random effects model. Meta-analysis of non-randomized
studies will be performed separately from meta-analysis of
randomized trials. A systematic narrative synthesis will be
provided with information presented in the text and tables
to summarize and explain the characteristics and findings
of the included studies. The narrative synthesis will ex-
plore the relationship and findings both within and be-
tween the included studies, in line with the guidance from
the Centre for Reviews and Dissemination [15].
We will perform several a priori sensitivity analyses to
understand the data and to identify any subpopulations
that may benefit from the use of intravenous immuno-
globulin. These analyses will include stratification of stud-
ies according to baseline immunoglobulin level (IgG ≤4,
IgG >4 but <7, IgG ≥7 g/L), intent of immunoglobulin use
(prophylaxis vs treatment), immunosuppressive regimen
used (e.g., cyclosporin vs tacrolimus, induction vs no in-
duction), and organ type (e.g., liver, kidney).
Reporting of the review
We will report our findings in accordance with guidance
of the PRISMA statement [15] and its checklist. A com-
pleted copy of the checklist will be provided in a supple-
ment to the main report (Additional file 2).
Discussion
In this systematic review, we will assess the treatment out-
come of hypogammaglobulinemia post solid organ trans-
plantation. We anticipate several challenges in this work.
These will include the possibility of considerable study
heterogeneity in terms of organ type, immunosuppressive
regimen, study design, and outcomes reported. The avail-
ability of high-quality studies addressing this topic may
also be limited. Studies may concentrate on a particular
type of solid organ transplantation, in which case the data
will be pooled and analyzed within the same type of trans-
plantation. This may limit the generalizability to other
types of solid organ transplantation but may provide for a
better-focused interpretation.
Despite several anticipated challenges, our systematic
review will provide important insights into the effects of
immunoglobulin replacement therapy or prophylactic
therapy in solid organ transplant recipients. The results
may have a direct impact on current practice and prac-
tice guidelines. The data will also serve as a starting
point for further research.
Additional files
Additional file 1: Search strategy. Serch terms and databases are
outlined. (DOCX 15.2 kb)
Additional file 2: PRISMA-P checklist. Report of compliance with
standard reporting guideline. (DOC 84 kb)
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